314 related articles for article (PubMed ID: 10882163)
1. Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
Clemett D; Lamb HM
Drugs; 2000 Jun; 59(6):1279-96. PubMed ID: 10882163
[TBL] [Abstract][Full Text] [Related]
2. Exemestane: a review of its use in postmenopausal women with breast cancer.
Deeks ED; Scott LJ
Drugs; 2009; 69(7):889-918. PubMed ID: 19441873
[TBL] [Abstract][Full Text] [Related]
3. Exemestane.
Scott LJ; Wiseman LR
Drugs; 1999 Oct; 58(4):675-80; discussion 681-2. PubMed ID: 10551437
[TBL] [Abstract][Full Text] [Related]
4. Exemestane in advanced breast cancer.
Buzdar A
Anticancer Drugs; 2000 Sep; 11(8):609-16. PubMed ID: 11081451
[TBL] [Abstract][Full Text] [Related]
5. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
Kaufmann M; Bajetta E; Dirix LY; Fein LE; Jones SE; Zilembo N; Dugardyn JL; Nasurdi C; Mennel RG; Cervek J; Fowst C; Polli A; di Salle E; Arkhipov A; Piscitelli G; Miller LL; Massimini G
J Clin Oncol; 2000 Apr; 18(7):1399-411. PubMed ID: 10735887
[TBL] [Abstract][Full Text] [Related]
6. Exemestane: a novel aromatase inactivator for breast cancer.
Jones SA; Jones SE
Clin Breast Cancer; 2000 Oct; 1(3):211-6. PubMed ID: 11899645
[TBL] [Abstract][Full Text] [Related]
7. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.
Kvinnsland S; Anker G; Dirix LY; Bonneterre J; Prove AM; Wilking N; Lobelle JP; Mariani O; di Salle E; Polli A; Massimini G
Eur J Cancer; 2000 May; 36(8):976-82. PubMed ID: 10885600
[TBL] [Abstract][Full Text] [Related]
8. Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review).
Crucitta E; Fornier MN; Locopo N; Silvestris N; Lorusso V; De Lena M
Int J Oncol; 2002 Jun; 20(6):1283-8. PubMed ID: 12012011
[TBL] [Abstract][Full Text] [Related]
9. Letrozole: a review of its use in postmenopausal women with breast cancer.
Simpson D; Curran MP; Perry CM
Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group.
Jones S; Vogel C; Arkhipov A; Fehrenbacher L; Eisenberg P; Cooper B; Honig S; Polli A; Whaley F; di Salle E; Tiffany J; Consonni A; Miller L
J Clin Oncol; 1999 Nov; 17(11):3418-25. PubMed ID: 10550136
[TBL] [Abstract][Full Text] [Related]
11. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
Michaud LB; Buzdar AU
Drug Saf; 1999 Oct; 21(4):297-309. PubMed ID: 10514021
[TBL] [Abstract][Full Text] [Related]
12. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer.
Wiseman LR; Adkins JC
Drugs Aging; 1998 Oct; 13(4):321-32. PubMed ID: 9805213
[TBL] [Abstract][Full Text] [Related]
13. [Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents].
Watanabe T; Sano M; Toi M; Saeki T; Kanda K; Miura S; Inaji H; Sono H; Saeki H; Nishimura R; Fujita Y
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1211-21. PubMed ID: 12146002
[TBL] [Abstract][Full Text] [Related]
14. Letrozole. A review of its use in postmenopausal women with advanced breast cancer.
Lamb HM; Adkins JC
Drugs; 1998 Dec; 56(6):1125-40. PubMed ID: 9878997
[TBL] [Abstract][Full Text] [Related]
15. Role of anti-aromatase agents in postmenopausal advanced breast cancer.
Murray R
Cancer Chemother Pharmacol; 2001 Oct; 48(4):259-65. PubMed ID: 11710624
[TBL] [Abstract][Full Text] [Related]
16. Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure.
Prescrire Int; 2001 Aug; 10(54):108-9. PubMed ID: 11718178
[TBL] [Abstract][Full Text] [Related]
17. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
Atalay G; Dirix L; Biganzoli L; Beex L; Nooij M; Cameron D; Lohrisch C; Cufer T; Lobelle JP; Mattiaci MR; Piccart M; Paridaens R
Ann Oncol; 2004 Feb; 15(2):211-7. PubMed ID: 14760111
[TBL] [Abstract][Full Text] [Related]
18. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
Jonat W; Howell A; Blomqvist C; Eiermann W; Winblad G; Tyrrell C; Mauriac L; Roche H; Lundgren S; Hellmund R; Azab M
Eur J Cancer; 1996 Mar; 32A(3):404-12. PubMed ID: 8814682
[TBL] [Abstract][Full Text] [Related]
19. The role of aromatase inactivators in the treatment of breast cancer.
Lønning PE
Int J Clin Oncol; 2002 Aug; 7(4):265-70. PubMed ID: 12202980
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitors for breast cancer in postmenopausal women.
Campos SM
Oncologist; 2004; 9(2):126-36. PubMed ID: 15047917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
